Talking Urology Podcast

Damien Bolton & Andrew Weickhardt discuss ‘The COVID conundrum: loss and lessons learned.

Prof Thomas Powles joins Talking Urology to discuss the new measures of success with IO agents.

A/Prof Shariat is currently professor and chairman of the department of urology, Medical University of Vienna General Hospital, Austria.

He is also adjunct professor of urology and medical oncology at Weill Cornell Medical Center, New York, and adjunct professor or urology at the University of Texas Southwestern Medical Center, Dallas, USA.

Prof Van Poppel is the Chairman of the Department of Urology at the University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium. He is a Board Member of the European Association of Urology (EAU), the European Society of Surgical Oncology and the European Organization for Research and Treatment of Cancer, where he is also Study Coordinator and Treasurer of the Genito-Urinary Group. He is Chairman of the Educational Office of the EAU and Director of the European School of Urology.

Join the star-studded cast of Talking Urology with Neal Shore, Ben Tran and Joseph Ischia as they unearth the mysteries of non-metastatic CRPC

Dr. Klotz is the founding editor of the Canadian Urology Association Journal and is now the Editor Emeritus. He is chairman of the Canadian Urology Research Consortium and is a widely published uro-oncologist with over 300 publications and 4 books.

His main research interest has been prostate cancer and was awarded the Queen’s Jubilee Medal for meritorious public service.

Dr. Lin is Professor and Chief of Urologic Oncology in the Department of Urology and holds the Bridges Endowed Professorship for Prostate Cancer Research at the University of Washington School of Medicine.

Dr. Lin’s major basic/translational research interests are in prostate chemoprevention and molecular/genomic biomarkers for aggressive prostate cancer, and his major clinical research efforts are in prostate cancer active surveillance and novel strategies in high-risk prostate cancer.

Dr. Nitti is a Professor of Urology and OB/GYN, Vice-Chairman of Urology, Director of the Female Pelvic Medicine and Reconstructive Surgery at New York University Langone Medical Center.

A graduate of the University of Medicine and Dentistry of New Jersey, Dr. Nitti completed his urology residency at SUNY Downstate in Brooklyn, NY and his fellowship in Female Urology, Neurourology, and Reconstructive Urology at UCLA. He is a Fellow of the American College of Surgeons and the American Board of Urology.

Dr. Quinn is currently the Medical Director of the Norris Cancer Hospital, the Head of Genitourinary Medical Oncology and Associate Professor of Medicine in the Division of Oncology, Keck School of Medicine, University of Southern California.

He is a medical oncologist and an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics.

Maurizio Brausi discusses his landmark paper on BCG in Intermediate & High-risk Ta, T1 Papillary Ca of the Bladder.